HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia

Pediatric Rheumatology

Volumn 8, Issue , 2010, Pages

  Stanevicha, Valda ^a   Eglite, Jelena ^a   Zavadska, Dace ^a   Sochnevs, Arturs ^a   Lazareva, Arina ^a   Guseinova, Dinara ^b   Shantere, Ruta ^b   Gardovska, Dace ^a  

^a RIGA STRADINS UNIVERSITY   (Latvia)

^b CHILDREN'S CLINICAL UNIVERSITY HOSPITAL   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HLA B27 ANTIGEN; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; ALLELISM; ARTHRITIS; ARTICLE; CHILD; DNA ISOLATION; DRUG EFFECT; DRUG INDICATION; ENTHESITIS; FEMALE; GENETIC ASSOCIATION; HUMAN; IDIOPATHIC DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LATVIA; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYARTHRITIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 77957779897     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-8-26     Document Type: Article

References (50)

1. Gäre BA. Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999, 17:367-374.
2. Cassidy JT, Petty RE, Laxer RM. Textbook of pediatric rheumatology. Elsevier 2005, Philadelphia, 5.
3. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology 2002, 41:1428-1435. 10.1093/rheumatology/41.12.1428, 12468825.
4. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed criteria for idiopathic arthritis: Durban 1997. Journal of Rheumatology 1998, 25:1991-1994.
5. Brewerton DA, Hart FD, Nicholls A, Caffrey M, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973, 1:904-907. 10.1016/S0140-6736(73)91360-3, 4123836.
6. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973, 288:704-706. 10.1056/NEJM197304052881403, 4688372.
7. Ball EJ, Khan MA. HLA-B27 polymorphism. Joint Bone Spine 2001, 68:378-382. 10.1016/S1297-319X(01)00294-9, 11707003.
8. Thomson W, Donn R. Juvenile idiopathic arthritis genetics - what's new? What's next?. Arthritis Res 2002, 4:302-306. 10.1186/ar591, 12223104.
9. Gensler L, Davis JC. Recognition and treatment of juvenile-onset spondyloarthritis. Curr Opin Rheumatol 2006, 18(5):507-511. 10.1097/01.bor.0000240363.09218.61, 16896291.
10. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369:767-778. 10.1016/S0140-6736(07)60363-8, 17336654.
11. Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. Juvenile-onset spondyloarthropathies. Pediatr Rheumatol 1997, 23:569-598.
12. Rachelefsky GS, Teresaki PI, Katz R. Increased prevalence of Bw27 in juvenile rheumatoid arthritis. N Engl J Med 1974, 290:892-893. 10.1056/NEJM197404182901608, 4544652.
13. Taurog Joel D. The Mystery of HLA-B27: If It Isn't One Thing, It's Another. Arthritis & Rheumatism 2007, 56(8):2478-2481.
14. McMichael A, Bowness P. HLA-B27: natural function and pathogenic role in spondyloarthritis. Arthritis Res 2002, 4(suppl 3):S153-S158. 10.1186/ar571, 12110134.
15. Hülsmeyer M, Hillig RC, Volz A, Rühl M, et al. HLA-B27 Subtypes Differentially Associated with Disease Exhibit Subtle Structural Alterations. J Biol Chem 2002, 277(49):47844-47853. 10.1074/jbc.M206392200, 12244049.
16. Akkoc N, Khan MA. Etiopathogenic role of HLA-B27 alleles in ankylosing spondylitis. APLAR Journal of Rheumatology 2005, 8:146-153.
17. Brooks CD. Sulfasalazine for the management of juvenile rheumatoid arthritis. J Rheumatol 2001, 28:845-853.
18. Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986, 13:124-125.
19. Van Rossum, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007, 66:1518-1524. 10.1136/ard.2006.064717, 17491099.
20. Ringold S, Wallace CA, Hart JA. Measuring Clinical Response and Remission in Juvenile Idiopathic Arthritis: Measures of Disease Activity. Curr Opin Rheumatol CME 2007, 19(5):471-476.
21. Giannini EH, Ruperto N, Ravelli A, Lovell DJ. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40(7):1202-1209.
22. Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. Am J Med Sci 1998, 316:239-249. 10.1097/00000441-199810000-00004, 9766485.
23. Frosch M, Ganser G, Herter B, et al. Treatment of juvenile rheumatoid pauciarthritis with sulphasalazine. Clin Exp Rheumatol 1995, 13:560-566.
24. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996, 23:360-366.
25. Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 1998, 17:359-363. 10.1007/BF01450892, 9805178.
26. Gedalia A, Barash J, Press J, Buskila D. Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis. Clin Rheumatol 1993, 12:511-514. 10.1007/BF02231781, 7907286.
27. Romicka AM, Siemienska-Rywik S, Rostropowicz-Denisiewicz K. An assessment of the results of sulfasalazine treatment in patients with juvenile rheumatoid arthritis. Reumatologia 1994, 32:221-225.
28. Van Rossum MAJ, Fiselier TJW, Fransen MJAM, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo controlled, multi-center study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998, 41:808-816. 10.1002/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T, 9588731.
29. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, et al. A 26 week randomised double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002, 61(10):941-942. 10.1136/ard.61.10.941, 1753917, 12228171.
30. Thomson W, Donn R. Juvenile idiopathic arthritis genetics - What's new? What's next?. Arthritis Res 2002, 4:302-306. 10.1186/ar591, 128941, 12223104.
31. Ahlenstiel G, Roomp K, Daumer M, Nattermann J, Vogel M, et al. Selective Pressures of HLA Genotypes and Antiviral Therapy on Human Immunodeficiency Virus Type 1 Sequence Mutation at a Population Level. Clin.Vaccine Immunol 2007, 14(10):1266-1273. 10.1128/CVI.00169-07, 2168106, 17715334.
32. Likanonsakul S, Rattanatham T, Feangvad S, Uttayamakul S, et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Research and Therapy 2009, 6:22. 10.1186/1742-6405-6-22, 2774340, 19845952.
33. Aimarri A, Al Dwick N, Al Kabi S, Sleem K, et al. Interferon- α Therapy in HCV Hepatitis: HLA Phenotype and Cirrhosis are Independent Predictors of Clinical Outcome. Human Immunol 1996, 59(4):239-242.
34. Fusco C, Andreone V, Coppola G, Luongo V, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001, 57:1976-1979.
35. Pappas D, Oksenberg J. Maximizing efficacy of therapy. Neurology 2010, 74:S62-S69. 10.1212/WNL.0b013e3181c980fb, 20038765.
36. Olivieri I, Scarano E, Gigliotti P, Padula A. Successful treatment of juvenile - onset HLA-B27- associated severe and refractory heel Thesitis with adalimumab documented by magnetic resonance imaging. Rheumatology 2006, 45(10):1315-1317. 10.1093/rheumatology/kel208, 16844703.
37. Shah P, Griffith S, Shandforth M, Fisher J, Dawes P, et al. Can gold therapy be used safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status. J Rheumatol 2004, 31(10):1903-5.
38. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992, 39:225-235. 10.1111/j.1399-0039.1992.tb01940.x, 1357775.
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988, 16:1215-1218. 10.1093/nar/16.3.1215, 334765, 3344216.
40. Bunce M, O'Neill CM, Barnardo MCN, Krausa P, Browning MJ, Morris PJ, et al. Photoytping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilising sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355-367. 10.1111/j.1399-0039.1995.tb03127.x, 8838344.
41. Mehta CR, Patel NR, Gay RJ. Pascal program by ELF Franco & N Compos-Filho Ludwig Cancer Institute: Mathematics Software StatCalc. 1985, 78:969-973. São Paulo, Brazil: Am. Stat. Assoc.
42. Murray KJ, Moroldo MB, Donnelly P, et al. Age specific effects of juvenile rheumatoid arthritis-associated alleles. Arthritis Rheum 1999, 42:1843-1853. 10.1002/1529-0131(199909)42:9<1843::AID-ANR8>3.0.CO;2-M, 10513798.
43. Blanco-Gelaz MA, Lopez-Vazquez A, Garcia-Fernandez S, Martinez-Borra J, Gonzalez S, Lopez-Larrea C. Genetic variability, molecular evolution, and geographic diversity of HLA-B27. Hum Immunol 2001, 62:1042-1050. 10.1016/S0198-8859(01)00299-3, 11543905.
44. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 1997, 49:67-69. 10.1111/j.1399-0039.1997.tb02713.x, 9027969.
45. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002, 41:1183-1189. 10.1093/rheumatology/41.10.1183, 12364641.
46. Pruunsild C, Uibo K, Liivamägi H, Tarraste S, et al. Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol 2007, 36:7-13. 10.1080/03009740601089259, 17454929.
47. Berntson L, Damgard M, et al. For the Nordic Paediatric Rheumatology Study HLA-B27 Predicts a More Extended Disease with Increasing Age at Onset in Boys with Juvenile Idiopathic Arthritis. J Rheumatol 2008, 35(10):2055-2061.
48. Chang JH, Mc Cluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol 2005, 50(4):364-388. 10.1016/j.survophthal.2005.04.003, 15967191.
49. Huhtinen M, Karma A. HLA-B27 typing in the categorisation of uveitis in a HLA-B27 rich population. Br J Ophthalmol 2000, 84(4):413-6. 10.1136/bjo.84.4.413, 1723428, 10729301.
50. Hashkes PJ, Laxer RM. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA 2005, 294:1671-1684. 10.1001/jama.294.13.1671, 16204667.